Oxybutynin Chloride NDC 72189-130

NDC codes

FDA NDC Directory

Product NDC (as listed)72189-130Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72189-0130Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72189-130-30	72189013030	30 TABLET in 1 BOTTLE (72189-130-30)Marketed from Nov 11, 2020

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Oxybutynin Chloride
Generic name (nonproprietary): oxybutynin chloride
Active ingredients: Oxybutynin chloride — 5 mg/1
Dosage form: Tablet
Route: Oral
Labeler: direct rx
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 071655
Marketing start: Nov 11, 2020
Listing expires: Dec 31, 2026
Other FDA classes: Cholinergic Muscarinic Antagonists (Mechanism)
Identifiers: Product ID 72189-130_2bece08b-b60b-a15e-e063-6394a90a3a13SPL ID 2bece08b-b60b-a15e-e063-6394a90a3a13SPL set ID b3d6d2a8-97c4-5bad-e053-2a95a90a155dRxCUI 863636, 863664UNII L9F3D9RENQ
Pharmacologic class: Cholinergic Muscarinic Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472189013030 followed by a unit qualifier and the quantity

Package 72189-0130-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 17, 2025.

Indications (excerpt from the label)

Oxybutynin chloride extended-release tablets are muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Oxybutynin chloride extended-release tablets are also indicated for the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida).

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 071655

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 071655
Product	Strength	Form · route	Labeler	Product NDC
Oxybutynin Chloride	Oxybutynin chloride 5 mg/1	TabletOral	Proficient Rx LP	63187-749
Oxybutynin Chloride	Oxybutynin chloride 5 mg/1	TabletOral	Bryant Ranch Prepack	71335-0519
Oxybutynin Chloride	Oxybutynin chloride 5 mg/1	TabletOral	Teva Pharmaceuticals USA, Inc.	50111-456